X4 Pharmaceuticals (XFOR) Return on Capital Employed (2018 - 2025)

X4 Pharmaceuticals has reported Return on Capital Employed for 8 years, with the latest figure at 43.17% in Q4 2025.

• For the quarter ending Q4 2025, Return on Capital Employed fell 1505.0% year-over-year to 43.17%; the trailing twelve-month figure through Dec 2025 stood at 43.17% (down 1505.0% YoY), and the FY2025 full-year result was 45.09%, down 1315.0% from the prior year.
• Return on Capital Employed for Q4 2025 stood at 43.17%, up from 89.21% in the prior quarter.
• The five-year high for Return on Capital Employed was 7.61% in Q1 2025, with the low at 132.92% in Q3 2022.
• Historically, Return on Capital Employed has averaged 70.72% across 5 years, with a median of 78.16% in 2022.
• The largest YoY upside for Return on Capital Employed was 10117 bps in 2025 against a maximum downside of 9779 bps in 2025.
• X4 Pharmaceuticals' Return on Capital Employed stood at 81.19% in 2021, then advanced by 4 bps to 78.07% in 2022, then declined by 0 bps to 78.25% in 2023, then jumped by 64 bps to 28.12% in 2024, then sank by 54 bps to 43.17% in 2025.
• The last three Return on Capital Employed figures came in at 43.17% (Q4 2025), 89.21% (Q3 2025), and 111.82% (Q2 2025), per Business Quant data.